Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma

1. Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma

9. Multiple MyelomaChoice of Induction Regimen

12. Multiple MyelomaCompeting Induction Regimens

14. Choice of Induction Regimen Use the best drugs early to get maximum remission for as long as possible, both for the standard-risk as well as the high-risk patients.

15. Multiple MyelomaEarly vs Delayed HDT/ASCT

16. Timing of HDT/ASCT Patients with no high-risk disease, who are responsive and tolerate therapy, may do extremely well with delayed HDT/ASCT.

18. Multiple MyelomaMaintenance Therapy

20. Consider No Maintenance For patients with standard-risk disease, stringent CR, normal FLC ratio, who are immunofixation negative in urine and serum, and have completely negative BM.

21. Consider Triplet Maintenance For patients with a truly high-risk disease (eg, stage III myeloma with high-risk cytogenetics).

23. Abbreviations

24. Abbreviations (cont)

25. References

26. References (cont)

27. References (cont)